Biotech Values

[Democritus_of_Abdera]

Regarding Monsanto’s antitrust inquiry...

For those interested, a concise and cogent presentation of anti-trust arguements against Monsanto is found in Diana Moss’s white paper which was quoted in the article jbog posted in #msg-43992457 (see http://www.antitrustinstitute.org/archives/files/AAI_Platforms%20and%20Transgenic%20Seed_102320091053.pdf ).

Diana Moss made the following comparison, albeit it was a tangential issue with respect to her main arguement:

At the same time, it is important to note that agricultural biotechnology and pharmaceutical innovation markets share much in common. Legislative approaches to the issue of generic drug entry (e.g., the Hatch-Waxman Act) have, in some part, eased competitive concerns, while at the same time unintentionally opening new ways for branded drugs to game the system. Whether a comparable legislative approach on the agricultural biotechnology side is possible remains to be seen. But legislative action could be motivated by the key role of the agricultural sector in the U.S. and world economies and the importance of agricultural products to the American consumer.